MK-0359, formerly known as L454560, is a selective and potent orally bioavailable PDE4 inhibitor for the treatment of chronic asthma. Over a 14-day treatment period, the orally bioavailable PDE4 inhibitor MK-0359 improved lower airway function, symptoms and rescue medication use in chronic asthma, although at the expense of gastrointestinal adverse experiences. References: Lu S, Liu N, Dass SB, Reiss TF, Knorr BA. Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma. Respir Med. 2009 Mar;103(3):342-7. doi: 10.1016/j.rmed.2008.10.024. Epub 2009 Jan 8. PubMed PMID: 19135348.

纯度：≥98%

CAS：346629-30-9